Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Ideaya Biosciences Inc’s stock clocked out at $34.34, up 1.93% from its previous closing price of $33.69. In other words, the price has increased by $1.93 from its previous closing price. On the day, 1.52 million shares were traded. IDYA stock price reached its highest trading level at $34.74 during the session, while it also had its lowest trading level at $33.1434.
Ratios:
To gain a deeper understanding of IDYA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.44 and its Current Ratio is at 12.44. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On September 18, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $50.
On September 04, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $41.Citizens JMP initiated its Mkt Outperform rating on September 04, 2025, with a $41 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IDYA now has a Market Capitalization of 3010464512 and an Enterprise Value of 2250815488. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.01 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at 10.477 whereas that against EBITDA is -10.909.
Stock Price History:
The Beta on a monthly basis for IDYA is 0.05, which has changed by 0.27758813 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, IDYA has reached a high of $36.55, while it has fallen to a 52-week low of $13.45. The 50-Day Moving Average of the stock is 13.17%, while the 200-Day Moving Average is calculated to be 46.92%.
Shares Statistics:
It appears that IDYA traded 1.20M shares on average per day over the past three months and 787290 shares per day over the past ten days. A total of 87.67M shares are outstanding, with a floating share count of 83.79M. Insiders hold about 4.42% of the company’s shares, while institutions hold 104.58% stake in the company. Shares short for IDYA as of 1763078400 were 8033340 with a Short Ratio of 6.71, compared to 1760486400 on 8481677. Therefore, it implies a Short% of Shares Outstanding of 8033340 and a Short% of Float of 10.8100004.
Earnings Estimates
The stock of Ideaya Biosciences Inc (IDYA) is currently drawing attention from 17.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.74 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$0.69 and -$1.48 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$3.51, with 17.0 analysts recommending between -$2.31 and -$4.63.
Revenue Estimates
In. The current quarter, 17 analysts expect revenue to total $5.95M. It ranges from a high estimate of $22.2M to a low estimate of -$1.6M. As of. The current estimate, Ideaya Biosciences Inc’s year-ago sales were $7M
A total of 18 analysts have provided revenue estimates for IDYA’s current fiscal year. The highest revenue estimate was $275M, while the lowest revenue estimate was $207.8M, resulting in an average revenue estimate of $217.28M. In the same quarter a year ago, actual revenue was $7M
